Chronic Obstructive Pulmonary Disease – Geographic Focus: China – COPD – China In-Depth (China)
COPD is a progressive respiratory condition that primarily affects adults, particularly smokers and individuals exposed to environmental pollutants. The COPD therapeutics market in China includes a range of well-established treatments, such as bronchodilators, corticosteroids, and combination therapies (e.g., Boehringer Ingelheim’s Spiriva, AstraZeneca’s Symbicort). Despite the availability of these treatments, there remains substantial unmet need, particularly for patients with frequent exacerbations and severe disease. Emerging targeted therapies—such as AstraZeneca’s benralizumab (Fasenra), GSK’s mepolizumab (Nucala), Chiesi Farmaceutici’s tanimilast—are likely to address this need and boost the COPD therapy market over the next 10 years. This report offers a thorough analysis of the COPD market in China, covering current disease management, lingering unmet needs, and the clinical and commercial potential of current and emerging drugs.
QUESTIONS ANSWERED
- What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?
- Which are the most commercially relevant drugs and why? What are interviewed experts’ insights into current treatment options?
- What are the key unmet needs in the management of COPD in China?
- Which emerging therapies have the most potential for uptake?
- What are the key market access considerations, and how will they impact the uptake of emerging therapies for COPD in China?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy in China.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.
- Gauge the commercial outlook and impact of key market events.
Release Date
April 2025
Geographies
China
Primary Research
Qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 pulmonologists in China
Epidemiology
Diagnosed prevalence of COPD in China, with urban and rural breakup. Clinically and market-relevant drug-treatable populations
Forecast
10-year, annualized, drug-level sales and patient share of key COPD therapies through 2034, based on primary and secondary market research to formulate bottom-up assumptions
Drug treatments
Coverage of key current and late-phase emerging therapies
Custom drug modeler
Integrated tool to input customized forecast assumptions (e.g., launch date, price)
